Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) EBITDA Margin (2018 - 2025)

Lipocine's EBITDA Margin history spans 8 years, with the latest figure at 2776.34% for Q3 2025.

  • For Q3 2025, EBITDA Margin changed N/A year-over-year to 2776.34%; the TTM value through Sep 2025 reached 126.79%, down 7296.0%, while the annual FY2024 figure was 0.09%, 57272.0% up from the prior year.
  • EBITDA Margin reached 2776.34% in Q3 2025 per LPCN's latest filing, down from 355.22% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 11817.87% in Q2 2021 to a low of 6995.38% in Q1 2023.
  • Average EBITDA Margin over 5 years is 281.38%, with a median of 284.11% recorded in 2025.
  • Peak YoY movement for EBITDA Margin: crashed -1234773bps in 2022, then surged 704127bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 78.39% in 2021, then plummeted by -776bps to 529.85% in 2022, then skyrocketed by 297bps to 1045.61% in 2023, then plummeted by -95bps to 51.02% in 2024, then tumbled by -5541bps to 2776.34% in 2025.
  • Per Business Quant, the three most recent readings for LPCN's EBITDA Margin are 2776.34% (Q3 2025), 355.22% (Q2 2025), and 1990.64% (Q1 2025).